Sign In
Buy BBIO
$65.48
+1.60 (+2.50%)
At Close: Jun 03, 2026
BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe
02:33am, Monday, 04'th Mar 2024
BridgeBio Pharma has granted German drugmaker Bayer an exclusive license to commercialize its heart disease drug in Europe, the companies said on Monday.
BridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out?
02:30am, Monday, 04'th Mar 2024
Bayer snagged commercial rights to BridgeBio's lead asset, acoramidis, in Europe for $310 million. BridgeBio stock is nearing a breakout.
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
02:30am, Monday, 04'th Mar 2024
- BridgeBio grants Bayer exclusive license to commercialize acoramidis as a treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in Europe
BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates
09:41am, Thursday, 22'nd Feb 2024
BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.96 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $0.87 per share a year ago.
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
07:30am, Thursday, 22'nd Feb 2024
- Submitted New Drug Application (NDA) to US Food and Drug Administration (FDA) for acoramidis for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) based on positive results of Phase 3
Analysts Estimate BridgeBio Pharma (BBIO) to Report a Decline in Earnings: What to Look Out for
11:06am, Thursday, 15'th Feb 2024
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- BridgeBio grants Kyowa Kirin exclusive license to develop and commercialize infigratinib for skeletal dysplasias in Japan
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
07:30am, Tuesday, 06'th Feb 2024
PALO ALTO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic disea
- Accepted with Prescription Drug User Fee Act (PDUFA) action date of November 29, 2024; FDA not currently planning to hold an advisory committee meeting to discuss application
- Phase 3 open-label, single-arm study conducted in Japan by BridgeBio licensing partner Alexion, AstraZeneca Rare Disease showed consistency with global ATTRibute-CM Phase III trial
Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics
07:00am, Tuesday, 30'th Jan 2024
SAN FRANCISCO , Jan. 30, 2024 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage b
3 Groundbreaking Biotech Stocks to Invest in Now
12:35pm, Monday, 29'th Jan 2024
Biotechnology companies are intriguing investment vehicles because they are part of a pretty speculative industry that allows investors to grow their investments rapidly — if they pick a company bef
BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck
05:19pm, Thursday, 11'th Jan 2024
BridgeBio Pharma, Inc. expects results from the phase 1/2 study, using gene therapy BBP-631 for the treatment of patients with congenital adrenal hyperplasia, in early 2024. The congenital adrenal hyp
BridgeBio Pharma's Robust Pipeline Could Benefit From A Partner
03:18am, Monday, 08'th Jan 2024
BridgeBio's FDA filing for acoramidis and advances in KRAS mutation cancer treatment contrast with growing financial losses. Acoramidis competes with Pfizer's ATTR-CM treatments; BBIO's oncology focus
2 Biotechs That Could Get Bought Out in 2024
06:45am, Wednesday, 03'rd Jan 2024
With several big pharmas set to lose patent protection for key drugs this decade, the merger and acquisition scene is widely expected to heat up in 2024. These two biotechs have repeatedly been rumore
